UB Paderborn / Katalog / Suche / in CDI

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2015-05, Vol.385 (9980), p.1853-1862

2015

Volltextzugriff (PDF)

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

The lancet oncology, 2013-12, Vol.14 (13), p.1348-1356

2013

Volltextzugriff (PDF)

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3396-3401

2012

Volltextzugriff (PDF)

Efficient Cross-Priming of Tumor Antigen-Specific T Cells by Dendritic Cells Sensitized with Diverse Anti-MICA Opsonized Tumor Cells

Proceedings of the National Academy of Sciences - PNAS, 2005-05, Vol.102 (18), p.6461-6466

2005

Volltextzugriff (PDF)

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

The New England journal of medicine, 2008-06, Vol.358 (25), p.2698-2703

2008

Volltextzugriff (PDF)

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Journal of clinical pharmacology, 2017-09, Vol.57 (9), p.1148-1158

2017

Volltextzugriff (PDF)

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

Cancer chemotherapy and pharmacology, 2013-07, Vol.72 (1), p.241-249

2013

Volltextzugriff (PDF)

279 PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS

Journal of hepatology, 2010, Vol.52, p.S117-S117

2010

Volltextzugriff (PDF)

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

Hepatology (Baltimore, Md.), 2010-09, Vol.52 (3), p.822-832

2010

Volltextzugriff (PDF)

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

British journal of haematology, 2016-12, Vol.175 (5), p.860-867

2016

Volltextzugriff (PDF)

Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis

Journal of molecular medicine (Berlin, Germany), 1996-11, Vol.74 (11), p.695-703

1996

Volltextzugriff (PDF)

Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes

The Journal of experimental medicine, 1994-03, Vol.179 (3), p.951-960

1994

Volltextzugriff (PDF)

Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3157-TPS3157

2023

Volltextzugriff (PDF)

Abstract CT244: Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT244-CT244

2023

Volltextzugriff (PDF)

Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7549-7549

2018

Volltextzugriff (PDF)

Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7547-7547

2018

Volltextzugriff (PDF)

Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8507-8507

2010

Volltextzugriff (PDF)

Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3023-3023

2009

Volltextzugriff (PDF)

Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.6568-6568

2015

Volltextzugriff (PDF)

Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8519-8519

2015

Volltextzugriff (PDF)

Recombinant IL-21 (rIL-21) in combination with sorafenib: Interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16008-16008

2008

Volltextzugriff (PDF)

Cable cleaning solvents: environmental issues and effective replacements

IEEE transactions on power delivery, 1992-04, Vol.7 (2), p.1023-1026

1992

Volltextzugriff (PDF)

Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS8613-TPS8613

2014

Volltextzugriff (PDF)

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.S36-S37

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Efficient Cross-Priming of Tumor Antigen-Specific T Cells by Dendritic Cells Sensitized with Diverse Anti-MICA Opsonized Tumor Cells

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

279 PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis

Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes

Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Abstract CT244: Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL)

Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM)

Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results

Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL

Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL

Recombinant IL-21 (rIL-21) in combination with sorafenib: Interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC)

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Cable cleaning solvents: environmental issues and effective replacements

Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Suchergebnisse filtern